The University of Chicago Header Logo

Connection

James Howard Tonsgard to Angiogenesis Inhibitors

Back to Details
This is a "connection" page, showing publications James Howard Tonsgard has written about Angiogenesis Inhibitors.
James Howard Tonsgard
Connection Strength
0.148
Angiogenesis Inhibitors
  1. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
    View in: PubMed
    Score: 0.148
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.